Pancreatic Cancer Research

ResearcherUniversity of OxfordNo recent work listed

Ruth J. Muschel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5656-5970; OpenAlex author ID A5064457809. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 3 papers · 2015: 2 papers · 2016: 3 papers · 2017: 2 papers

Papers 11

  1. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-2833↗
  2. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. Co-author DOI 10.15252/emmm.201606674↗
  3. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.10038↗
  4. Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.12022↗
  5. The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.6770↗
  6. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. Last author DOI 10.1016/j.bbcan.2014.12.001↗
  7. IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer. Co-author DOI 10.1080/2162402x.2015.1027473↗
  8. The stromal compartments in pancreatic cancer: are there any therapeutic targets? First author DOI 10.1016/j.canlet.2013.09.039↗
  9. Contextual regulation of pancreatic cancer stem cell phenotype and radioresistance by pancreatic stellate cells. Co-author DOI 10.1016/j.radonc.2014.03.014↗
  10. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Co-author DOI 10.18632/oncotarget.2519↗
  11. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Co-author DOI 10.4161/cbt.21093↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Emmanouil Fokas · 7 shared papers, 2012–2017 · strength 0.38
  2. Zenobia D’Costa · 5 shared papers, 2016–2017 · strength 0.29
  3. Thomas Baptist Brunner · 5 shared papers, 2012–2015 · strength 0.26
  4. Abul Kalam Azad · 4 shared papers, 2016–2017 · strength 0.23
  5. Serena Lunardi · 4 shared papers, 2014–2015 · strength 0.23
  6. Angela Diana · 3 shared papers, 2016–2017 · strength 0.17
  7. Lai Mun Wang · 3 shared papers, 2016 · strength 0.16
  8. Owen James Sansom · 3 shared papers, 2014–2017 · strength 0.16
  9. Keaton Ian Jones · 2 shared papers, 2017 · strength 0.12
  10. Somnath Mukherjee · 2 shared papers, 2015–2016 · strength 0.11
  11. Eric E. O’Neill · 2 shared papers, 2016–2017 · strength 0.11
  12. Osama Al‐Assar · 2 shared papers, 2014 · strength 0.08
  13. Eric O’Neill · 1 shared paper, 2015 · strength 0.06
  14. Alex Nicolas Gordon-Weeks · 1 shared paper, 2015 · strength 0.06
  15. Nigel Balfour Jamieson · 1 shared paper, 2014 · strength 0.03
  16. Colin J. McKay · 1 shared paper, 2014 · strength 0.03
  17. Klaus‐Peter Janssen · 1 shared paper, 2014 · strength 0.03
  18. Remko Prevo · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.